Colorado Hepatitis C Support Groups

For individuals infected with hepatitis C and family members affected by hepatitis C.  Free and confidential monthly meetings.  New members always welcome.

Metro-Denver

May is Hepatitis Awareness Month

Third Annual National Hepatitis Testing Day 

As part of Hepatitis Awareness Month, May 19 is National Hepatitis Testing Day.  This annual event was created by the CDC to increase awareness of the importance of getting tested for hepatitis C if you are a baby boomer or have a risk factor.  Hep C Connection has organized Colorado's testing day activities, under contract with Colorado Department of Public Health and Environment.  This year, free hepatitis C screening will be offered throughout Colorado to baby boomers and any person with a risk factor.  See below for a list of testing sites in Colorado.  Not in Colorado? Click here to find a testing site in your area. 

Hep C Connection at Colorado 9Health Fairs

We exhibited at seven 9Health Fairs in April and will be at five additional fairs during May and June. Three of the upcoming fairs will offer hepatitis C testing.  We'll be there to answer any questions that attendees have about hepatitis.  You can register for a 9Health Fair here.  The 9Health Fair hours are from 7:00 am to 12:00 pm. 

May 1

Windsor Gardens

595 S Clinton St, Denver, CO

May 2*

Trinity Church at Downtown YMCA

25 E. 16th Ave, Denver, CO

May 3*

Erie Community Center

450 Powers St, Erie, CO

May 17

Waterstone Church

5890 S Alkire St, Littleton, CO

                  June 1*

       Fillmore Auditorium

1510 Clarkson St, Denver, CO    

* These sites will offer hepatitis C testing.  The CDC recommends that any person born between 1945 and 1965 be tested for hepatitis C at least once in their lifetime.  The CDC also recommends that any person with a risk factor for hepatitis C infection be tested.

Free HCV & HBV Class for Prevention Providers on May 15, 2014 in Durango

Buy Your Tickets for a Day of Baseball in the Rocky Mountain West 

World Hepatitis Day is an annual event held on July 28 and this year, Hep C Connection invites you, your family, and friends to a Rockies baseball game to recognize this very important day.  It'll be a fun afternoon of baseball that raises funds for Hep C Connection's prevention and support programs and increases awareness of the global burden of liver disease. We hope you'll join us in cheering on the Colorado Rockies as they go up against the Pittsburgh Pirates.  You'll be on the edge of your seat as the Rockies, ranked 22nd in the 2013 regular season, play their best to beat the Pirates, a team that finished just two spots ahead of them in 20th place.  Here are the details on the game:

The Colorado Rockies against the Pittsburgh Pirates

Date: Sunday, July 27, 2014

Time: 2:10 P.M.

Price: $35/ticket

Seats: Section 117, rows 25 through 30

To purchase tickets: Call (720) 917-3965 or send an email to Nancy Steinfurth, nsteinfurth@hepc-connection.org 

New Drug Applications Submitted to the FDA for Treatment of Genotype 1 Infection

Abbvie Submits New Drug Application to U.S. Food and Drug Administration (FDA) For its Investigational, all-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

04/22/2014 / Abbvie PRNewswire

Abbvie submitted a New Drug Application to the FDA for approval of a new regimen to treat adult patients with genotype 1 hepatitis C infection.  The regimen includes ritonavir co-formulated with ombitasvir, and dasabuvir with or without ribavirin.  

Full Article    

Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection

4/7/2014 / Gilead Business Wire 

The FDA has given priority review to Gilead's New Drug Application for the approval of a new regimen to treat adult patients with genotype 1 hepatitis C infection.  The combination includes ledipasvir and sofosbuvir.  Gilead expects a decision from the FDA by October 10, 2014.

Full Article 

Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to U.S. FDA for the Treatment of Hepatitis C

4/7/2014 / Bristol-Myers Squibb Company Business Wire 

Bristol-Myers Squibb submitted a New Drug Application to the FDA for approval of a new drug combination to treat adult patients with hepatitis C genotype 1b infection.  The combination includes daclatasvir and asunaprevir.

Full Article 

Featured HCV Clinical Trials

2014 Region VIII Viral Hepatitis Summit